H.C. Wainwright raised the firm’s price target on Amylyx (AMLX) to $16 from $12 and keeps a Buy rating on the shares after the company announced the Phase 3 LUCIDITY trial of avexitide is currently underway with the topline data expected in the first half of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances
- Amylyx reports Q1 EPS (42c), consensus (50c)
- Leerink upgrades Amylyx on avexitide growth opportunity
- Amylyx upgraded to Outperform from Market Perform at Leerink
- Amylyx doses first participant in Phase 3 LUCIDITY trial of avexitide